Table 1.

Demographic Data of the Patients Treated With Tyrosine Kinase Inhibitors

Variables	Gefitinib (n = 83)	Erlotinib (n = 36)	Afatinib (n = 28)	p Value
Median age [year (range)]	75 (50–95)	72 (52–87)	68 (37–82)	0.014
Sex				0.849
Female	54	22	19
Male	29	14	9
Smoking status				0.153
Never	58	18	22
Former	14	13	5
Current	9	2	1
Unknown	2	3	0
Histological subtype				0.120
Adenocarcinoma	78	33	23
Squamous cell carcinoma	1	0	3
Other	4	3	2
Clinical stage				0.742
3A	20	10	8
3B	5	3	3
4	58	23	16
Recurrent	0	0	1